 |
JIFACTOR:Publisher: Peytchinski, Gospodin Iliev
ISSN: 1312 773X (Online)
Issue: 2014, vol. 20, issue 6
Subject Collection: Medicine
Pages: 560-564
DOI: 10.5272/jimab.2014206.560
Published online: 23 December 2014
J of IMAB 2014 Oct-Dec;20(6):560-564
THROMBOCYTOSIS AS PROGNOSTIC FACTOR FOR SURVIVAL IN PATIENTS WITH ADVANCED NON SMALL CELL LUNG CANCER TREATED WITH FIRST- LINE CHEMOTHERAPY.
Deyan Davidov 
.
Department of Medical Oncology, Oncological Center - UMHAT "Dr Georgi Stranski", Medical University, Pleven, Bulgaria.
ABSTRACT:
Objective: The aim of this study was to evaluate elevated platelet count as a prognostic factor for survival in patients with advanced (stage IIIB/ IV) non- small cell lung cancer (NSCLC) receiving first- line chemotherapy.
Methods: From 2005 to 2009 three hundreds forty seven consecutive patients with stage IIIB or IV NSCLC, treated in Department of Medical Oncology, UMHAT "Dr Georgi Stranski" entered the study. The therapeutic regimens included intravenous administration of platinum- based doublets. Survival analysis was evaluated by Kaplan- Meier test. The influence of pretreatment thrombocytosis as prognostic factor for survival was analyzed using multivariate stepwise Cox regression analyses.
Results: Elevated platelet counts were found in 78 patients. The overall survival for patients without elevated platelet counts was 9,6 months versus 6,9 months for these with thrombocytosis. In multivariate analysis as independent poor prognostic factors were identified: stage, performance status and elevated platelet counts.
Conclusions: These results indicated that platelet counts as well as some clinical pathologic characteristics could be useful prognostic factors in patients with unresectable NSCLC.
Key words: Prognostic factors, Thrombocytosis, Non small cell lung cancer, Survival,
- Download FULL TEXT /PDF 572 KB/
Please cite this article in PubMed Style or AMA (American Medical Association) Style:
Davidov DN. Thrombocytosis as Prognostic Factor for Survival in Patients with Advanced Non Small Cell Lung Cancer Treated with First- Line Chemotherapy. J of IMAB. 2014 Oct-Dec;20(6):560-564. http://dx.doi.org/10.5272/jimab.2014206.560
Correspondence to: Dr Deyan Davidov, Department of Medical Oncology, Oncological Center, Medical University, Pleven; 1, "St. Kliment Ohridsky" Str., 5000 Pleven, Bulgaria; E-mail: dean_davidov@abv.bg
REFERENCES:
1. Siegel R, Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin. 2012 Jan-Feb; 62(1):10-29. [PubMed] [CrossRef]
2. Kim DN, Nam TK, Choe KS, Choy H. Personalized combined modality therapy for locally advanced non-small cell lung cancer. Cancer Res Treat. 2012 Jun;44(2):74-84. [PubMed] [CrossRef]
3. Lee DS, Kim YS, Kang JH, Lee SN, Kim YK, Ahn MI, et al. Clinical responses and prognostic indicators of concurrent chemoradiation for non- small cell lung cancer. Cancer Res Treat. 2011 Mar;43(1):32-41. [PubMed] [CrossRef]
4. Rapp E, Pater JL, Willan A, Cormier Y, Murray N, Evans WK, et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer- report of a Canadian multicenter randomized trial. J Clin Oncol. 1988 Apr;6(4);633- 641. [PubMed]
5. Bunn PA Jr, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non- small cell lung cancer: a review of the literature and future directions. Clin Cancer Res. 1988 May;4(5);1087-1100. [PubMed]
6. Schiller JH, Harrington D, Belani, CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non- small- cell lung cancer. New Eng J Med. 2002 Jan;346(2);92-98. [PubMed] [CrossRef]
7. O’Connell JP, Kris MG, Gralla RJ, Groshen S, Truat A, Fiore JJ, et al. Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small- cell lung cancer treated with combination chemotherapy. J Clin Oncol. 1986 Nov;4(11);1604-1614. [PubMed]
8. Berghmans T, Paesmans M, Sculier JP. Prognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic and new biological variables. Ther Adv Med Oncol. 2011 May;3(3):127-138. [PubMed] [CrossRef]
9. Unsal E, Atalay F, Atikcan S, Yilmaz A. Prognostic significance of hemostatic parameters in patients with lung cancer. Respir Med. 2004 Feb;98(2):93-98. [PubMed]
10. van Doormaal FF, Raskob GE, Davidson BL, Decousus H, Gallus A, Lensing AW, et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thromb Haemost. 2009 Apr;101(4):762-769. [PubMed] [CrossRef]
11. Pedersen L, Milman N. Prognostic significance of thrombocytosis in patients with primary lung cancer. Eur Respir J. 1996 Sep;9(9):1826-1830. [PubMed] [CrossRef]
12. Gonzalez Barcala FJ, Garcia Prim JM, Moldes Rodriguez M, Alvarez Fernandez J, Rey Rey MJ, Pose Reino A, et al. Platelet count: association with prognosis in lung cancer. Med Oncol. 2010 Jun;27(2):357‑ 362. [PubMed] [CrossRef]
13. Aoe K, Hiraki A, Ueoka H, Kiura K, Tabata M, Tanaka M, et al. Thrombocytosis is a useful prognostic indicator in patients with lung cancer. Respiration, 2004 Mar-Apr;71(2):170-173. [PubMed] [CrossRef]
14. Tomita M, Shimuzu T, Hara M, Ayabe T, Onitsuka T. Impact of preoperative haemoglobin level on survival of non- small lung cancer patients. Anticancer Res. 2008 May-Jun;28(3B):1947-1950. [PubMed]
15. Engan T, Hannisdal E. Blood analyses as prognostic factors in primary lung cancer. Acta Oncol. 1990; 29(2): 151-154. [PubMed]
16. Constantini V, Zacharski L, Moritz T, Edwards R. The platelet count in carcinoma of the lung and colon. Thromb Haemost. 1990 Dec;64(4):501- 505. [PubMed]
17. Brambilla E, Travis WD, Colby TV, Corrinz B, Shimosato Y. The new World Health Organization classification of lung tumours. Eur Respir J. 2001 Dec;18(6):1059-1068. [PubMed] [CrossRef]
18. AJCC (American Joint Committee on Cancer) Cancer Staging Manual, 6th ed, Greene FL, Page DL, Fleming ID, et al. (Eds). Springer-Verlag, New York, 2002.
19. Therrase P, Arbuch S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst.. 2000 Feb;92(3):205-216. [PubMed] [CrossRef]
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958 Jun;53(282);457-481. Published online: 12 Apr 2012. [CrossRef]
21. Peto R, Pike MC, Armitage P, Breslow N, Cox D, Howard S, et al. Design and analysis of randomized clinical trials requiring prolonged observations in each patient II. Analysis and examples. Br J Cancer. 1977 Jan;35(1);1-39. [PubMed]
22. Diehl WL, Mandelbaum I, The significance of thrombocytosis in patients with carcinoma of the lung. Surg Gynecol Obstet. 1983 Feb;156(2):187-188. [PubMed]
23. Tomita M, Shimuzu T, Hara M, Ayabe T, Onitsuka T. Prognostic impact of thrombocytosis in resectable non- small lung cancer. Interact Cardiovasc Thorac Surg. 2008 Aug;7(4):613-615. [PubMed] [CrossRef]
24. Dineen SP, Roland CL, Toombs JE, Kelher M, Silliman CC, Brekken RA, et al. The acellular fraction of stored platelets promotes tumor cell invasion. J Surg Res. 2009 May;153(1):132-137. [PubMed] [CrossRef]
Received: 28 September 2014
Published online: 23 December 2014